Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation

Alkem launches ceramide-boosting moisturizing lotion for skin barrier repair

FDA approves first immunotherapy for recurrent respiratory papillomatosis

Tonix receives FDA approval of Tonmya for treatment of fibromyalgia

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

The projected business potential is around US$ 1 million in the first year

Shanmuga Hospital commissions advanced PH impedance and manometry system

This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.

FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients

Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent